GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Book Value per Share

Infant Bacterial Therapeutics AB (OSTO:IBT B) Book Value per Share : kr12.64 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Book Value per Share?

Infant Bacterial Therapeutics AB's book value per share for the quarter that ended in Dec. 2024 was kr12.64.

During the past 12 months, Infant Bacterial Therapeutics AB's average Book Value Per Share Growth Rate was -44.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -28.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -20.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Infant Bacterial Therapeutics AB was 90.70% per year. The lowest was -28.90% per year. And the median was 4.40% per year.

Infant Bacterial Therapeutics AB's current price is kr50.40. Its book value per share for the quarter that ended in Dec. 2024 was kr12.64. Hence, today's PB Ratio of Infant Bacterial Therapeutics AB is 3.99.

During the past 11 years, the highest P/B Ratio of Infant Bacterial Therapeutics AB was 10.02. The lowest was 0.62. And the median was 1.92.

Warning Sign:

Infant Bacterial Therapeutics AB stock PB Ratio (=4.41) is close to 5-year high of 4.41.


Infant Bacterial Therapeutics AB Book Value per Share Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Book Value per Share Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.21 35.21 29.55 22.65 12.64

Infant Bacterial Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.65 20.59 17.57 15.15 12.64

Competitive Comparison of Infant Bacterial Therapeutics AB's Book Value per Share

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's PB Ratio falls into.


;
;

Infant Bacterial Therapeutics AB Book Value per Share Calculation

Infant Bacterial Therapeutics AB's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(170.26-0.00)/13.47
=12.64

Infant Bacterial Therapeutics AB's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(170.26-0.00)/13.47
=12.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Infant Bacterial Therapeutics AB Book Value per Share Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines